Last reviewed · How we verify
Sulfonylurea or Pioglitazone
At a glance
| Generic name | Sulfonylurea or Pioglitazone |
|---|---|
| Sponsor | University of Leicester |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (PHASE4)
- HbA1c Variability in Type II Diabetes (NA)
- A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (PHASE4)
- Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen (PHASE4)
- Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan (PHASE4)
- Trial for People With Established Type 2 Diabetes During Ramadan (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sulfonylurea or Pioglitazone CI brief — competitive landscape report
- Sulfonylurea or Pioglitazone updates RSS · CI watch RSS
- University of Leicester portfolio CI